Showing 4941-4950 of 5964 results for "".
- ALASTIN Adds to Board of Directorshttps://practicaldermatology.com/news/alastin-adds-to-board-of-directors/2457837/Ann Rhoads and Elisabeth Sandoval are now members of ALASTIN Skincare, Inc’s Board of Directors. Ms. Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as Chief Financial Officer of
- Coming Soon: L'Oréal and SkinCeuticals Unveil CUSTOM D.O.S.Ehttps://practicaldermatology.com/news/coming-soon-loral-and-skinceuticals-unveil-custom-dose/2457841/L'Oréal is unveiling CUSTOM D.O.S.E (D.O.S.E), a personalized skincare service, at Fast Company's Grill in Austin. Developed by L'Oréal's Technology Incubator in partnership with L'Or&eacut
- Sensus Healthcare Launches New Line of Laser Systems for Clinical and Aesthetic Dermatologyhttps://practicaldermatology.com/news/sensus-healthcare-launches-new-line-of-laser-systems-for-clinical-and-aesthetic-dermatology/2457846/Sensus Healthcare, Inc. has launched Sensus Laser Systems, a unique multi-platform line of high-quality, cost-effective dermatological lasers to complement its existing superficial radiation therapy (SRT) system, which is used for non-invasive treatment of non-melanoma skin cancers and keloids. T
- Novartis' Xolair Recommended in New Global Chronic Urticaria Guidelinehttps://practicaldermatology.com/news/novartis-xolair-recommended-in-new-global-chronic-urticaria-guideline/2457849/A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for pat
- CareCredit Moves Into Day and Med Spa Marketshttps://practicaldermatology.com/news/carecredit-moves-into-day-and-med-spa-markets/2457847/CareCredit is expanding into the day and medical spa markets. As part of this new program, CareCredit partnered with both the American Med Spa Association and the Spa Industry Association to bring the benefits of CareCredit to their practices. Providers can now offer clients acces
- Medimetriks Divests Xepi Cream to Cutanea Life Scienceshttps://practicaldermatology.com/news/medimetriks-divests-xepi-cream-to-cutanea-life-sciences/2457850/Medimetriks Pharmaceuticals, Inc. divested exclusive US rights for Xepi (ozenoxacin cream) 1% to Cutanea Life Sciences, Inc. for up to $30 million, with $29 million to be paid in 2018, plus the assumption of $5 mil
- Episciences Launches New Eczema Creamhttps://practicaldermatology.com/news/episciences-launches-new-eczema-cream/2457851/Episciences, Inc. introduced a new Epionce Renewal Calming Cream, a formula that helps soothe as it replenishes moisture in the skin barrier. Renewal Calming Cream helps relieve the most stubborn symptoms associated with eczema. Ideal for patients with eczema and very dry, sensitive skin, t
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Botox Biosimilar in the Workshttps://practicaldermatology.com/news/botox-biosimilar-in-the-works/2457853/Mylan N.V. and Revance Therapeutics, Inc. are partnering to develop a biosimilar to BOTOX® (onabotulinumtoxinA). "We have reviewed the work done to date by Revance and we are extremely excited and confident
- Skin Microbiome May Protect Against Skin Cancerhttps://practicaldermatology.com/news/skin-microbiome-may-protect-against-skin-cancer/2457857/Beneficial skin bacteria may protect against skin cancer, according to a new study in Science Advances. “We have identified a strain of Staphylococcus epidermidis, common on healthy human skin, that exerts a selective ability to inhibit the growth of some cancers,” sa